The Enroll-HD Clinical Trial Committee (CTC) is the entry point for industry and academic sponsors seeking provision of high-quality clinical advice and guidance, and/or access to Enroll-HD platform operational support for conducting interventional therapeutic trials in Huntington’s Disease (HD). The CTC has so far provided advice and support to multiple small biotech and major pharmaceutical company partners working in HD.
The CTC comprises an operational management team and an independent advisory committee composed of HD expert clinicians and scientists, and has 3 main remits: (i) provision of advice on protocol design and clinical development topics, with access to experts from within the CHDI Clinical Department (imaging, biomarkers, clinical outcomes, disease modelling) and/or independent HD experts from the CTC advisory panel; (ii) review of final protocols by independent HD experts to allow access to Enroll-HD platform operational support (e.g. in-silico feasibility, site identification, recruitment support; see Enroll-HD Platform resource poster); (iii) oversight of the HD Clinical Trial Site Certification Program, open to Enroll-HD and non-Enroll-HD sites with the capabilities and expertise to be considered suitable for HD clinical trials. A Site Certification application group assesses sites’ suitability against a set of basic generic industry-agreed criteria.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.